VAM
KDNY

Visium Asset Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Visium Asset Management’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-5,881
Closed -$570K – 900
2015
Q3 		$570K Sell
5,881
-972
-14% -$116K 0.01% 560
2015
Q2 		$1.04M Buy
+6,853
New +$1.13M 0.01% 522

Other funds holding KDNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
MAM
Marquette Asset Management Minneapolis, Minnesota $779M AUM 23.4% 1-Year Est. Return

Visium Asset Management's KDNY Position: Q4 2015 in Review

Visium Asset Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q4 2015, closing a stake of 5,881 shares — an estimated $570K sold.

Visium Asset Management first reported a position in KDNY in Q2 2015 and held it in 2 quarters. The position peaked at $1.04M in Q2 2015. 87 funds tracked by Wall St. Rank hold KDNY as of Q4 2015.

  • Visium Asset Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q4 2015 after selling out during the quarter.
  • Visium Asset Management sold 5,881 Chinook Therapeutics, Inc. Common Stock shares in Q4 2015, an estimated $570K.
  • Visium Asset Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2015 and held it in 2 quarters.
  • Visium Asset Management's Chinook Therapeutics, Inc. Common Stock position peaked at $1.04M in Q2 2015.
  • 87 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q4 2015.

Based on Visium Asset Management's 13F filing for Q4 2015, filed 12 Feb 2016.